Natural Product (NP) Details
| General Information of the NP (ID: NP3947) | |||||
|---|---|---|---|---|---|
| Name |
Toosendanin
|
||||
| Synonyms |
Toosendanin; Chuanliansu; 58812-37-6; 12-Acetoxyamoorastatin; CHEMBL503044; HY-N0263; ZINC8214370; MFCD00210564; AKOS025311566; AS-56295; CS-0008285; Y0207; 812T376; Q-100679; [(1S,2R,4R,5R,6S,8R,10S,11S,12R,14R,15R,16R,19S,21R)-4-Acetyloxy-6-(furan-3-yl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.01,14.02,11.05,10.08,10]henicosan-21-yl] acetate
Click to Show/Hide
|
||||
| Species Origin | Melia azedarach ... | Click to Show/Hide | |||
| Melia azedarach | |||||
| Disease | Malaria [ICD-11: 1F40] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.419
MDCK Permeability
-5.037
PAMPA
+++
HIA
- -
Distribution
VDss
-0.476
PPB
49.7%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+
HLM Stability
-
Excretion
CLplasma
7.631
T1/2
2.296
Toxicity
DILI
++
Rat Oral Acute Toxicity
+++
FDAMDD
+++
Respiratory
+++
Human Hepatotoxicity
+
Ototoxicity
++
Drug-induced Nephrotoxicity
+++
Drug-induced Neurotoxicity
- -
Hematotoxicity
-
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C30H38O11
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C46C(O6)CC5C7=COC=C7)C)OC(=O)C)C)O)C)O)O
|
||||
| InChI |
1S/C30H38O11/c1-13(31)39-20-10-19(34)29-12-38-25(36)26(20,3)17(29)9-18(33)28(5)23(29)22(35)24(40-14(2)32)27(4)16(15-6-7-37-11-15)8-21-30(27,28)41-21/h6-7,11,16-21,23-25,33-34,36H,8-10,12H2,1-5H3/t16-,17-,18+,19-,20+,21+,23-,24-,25+,26+,27+,28+,29+,30+/m0/s1
|
||||
| InChIKey |
NAHTXVIXCMUDLF-RFNFAWMESA-N
|
||||
| CAS Number |
CAS 58812-37-6
|
||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Regorafenib | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | DVL2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | GSK-3B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | WWOX | Molecule Info | |||
| In-vitro Model | MHCC97-L | CVCL_4973 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
TSN and RGF combination (TRC) synergistically inhibited the proliferation and migration of MHCC-97L cells. The upregulation of WWOX (WW-domain containing oxidoreductase) played a vital role in the HCC cell growth treated with TRC. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Epidermal growth factor receptor (EGFR) | Molecule Info | [3] | |
| STAT factor 3 (STAT3) | Molecule Info | [3] | ||
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Ras signaling pathway | |||
| 4 | Rap1 signaling pathway | |||
| 5 | Calcium signaling pathway | |||
| 6 | Cytokine-cytokine receptor interaction | |||
| 7 | HIF-1 signaling pathway | |||
| 8 | FoxO signaling pathway | |||
| 9 | Endocytosis | |||
| 10 | PI3K-Akt signaling pathway | |||
| 11 | Dorso-ventral axis formation | |||
| 12 | Focal adhesion | |||
| 13 | Adherens junction | |||
| 14 | Gap junction | |||
| 15 | Regulation of actin cytoskeleton | |||
| 16 | GnRH signaling pathway | |||
| 17 | Estrogen signaling pathway | |||
| 18 | Oxytocin signaling pathway | |||
| 19 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 20 | Hepatitis C | |||
| 21 | Pathways in cancer | |||
| 22 | Proteoglycans in cancer | |||
| 23 | MicroRNAs in cancer | |||
| 24 | Pancreatic cancer | |||
| 25 | Endometrial cancer | |||
| 26 | Glioma | |||
| 27 | Prostate cancer | |||
| 28 | Melanoma | |||
| 29 | Bladder cancer | |||
| 30 | Non-small cell lung cancer | |||
| 31 | Central carbon metabolism in cancer | |||
| 32 | Choline metabolism in cancer | |||
| 33 | Chemokine signaling pathway | |||
| 34 | Signaling pathways regulating pluripotency of stem cells | |||
| 35 | Jak-STAT signaling pathway | |||
| 36 | Prolactin signaling pathway | |||
| 37 | Adipocytokine signaling pathway | |||
| 38 | Toxoplasmosis | |||
| 39 | Hepatitis B | |||
| 40 | Measles | |||
| 41 | Epstein-Barr virus infection | |||
| 42 | Viral carcinogenesis | |||
| 43 | Acute myeloid leukemia | |||
| 44 | Inflammatory bowel disease (IBD) | |||
| NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
| 2 | EGFR1 Signaling Pathway | |||
| Panther Pathway | Cadherin signaling pathway | Click to Show/Hide | ||
| 2 | EGF receptor signaling pathway | |||
| 3 | Angiogenesis | |||
| 4 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 5 | Interleukin signaling pathway | |||
| 6 | JAK/STAT signaling pathway | |||
| 7 | PDGF signaling pathway | |||
| 8 | Ras Pathway | |||
| 9 | CCKR signaling map ST | |||
| Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
| 2 | Signaling events mediated by PTP1B | |||
| 3 | Arf6 signaling events | |||
| 4 | Signaling events mediated by TCPTP | |||
| 5 | Thromboxane A2 receptor signaling | |||
| 6 | SHP2 signaling | |||
| 7 | Regulation of Telomerase | |||
| 8 | EGF receptor (ErbB1) signaling pathway | |||
| 9 | EGFR-dependent Endothelin signaling events | |||
| 10 | Posttranslational regulation of adherens junction stability and dissassembly | |||
| 11 | Direct p53 effectors | |||
| 12 | ErbB1 downstream signaling | |||
| 13 | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| 14 | E-cadherin signaling in keratinocytes | |||
| 15 | ErbB receptor signaling network | |||
| 16 | Internalization of ErbB1 | |||
| 17 | Stabilization and expansion of the E-cadherin adherens junction | |||
| 18 | a6b1 and a6b4 Integrin signaling | |||
| 19 | Syndecan-3-mediated signaling events | |||
| 20 | GMCSF-mediated signaling events | |||
| 21 | IL27-mediated signaling events | |||
| 22 | IL12-mediated signaling events | |||
| 23 | Signaling events mediated by HDAC Class I | |||
| 24 | IL2-mediated signaling events | |||
| 25 | CXCR4-mediated signaling events | |||
| 26 | IFN-gamma pathway | |||
| 27 | ErbB2/ErbB3 signaling events | |||
| 28 | IL6-mediated signaling events | |||
| 29 | PDGFR-beta signaling pathway | |||
| 30 | Neurotrophic factor-mediated Trk receptor signaling | |||
| 31 | IL23-mediated signaling events | |||
| 32 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 33 | FGF signaling pathway | |||
| 34 | RAC1 signaling pathway | |||
| 35 | Notch-mediated HES/HEY network | |||
| 36 | IL12 signaling mediated by STAT4 | |||
| Reactome | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | Click to Show/Hide | ||
| 2 | SHC1 events in ERBB2 signaling | |||
| 3 | PLCG1 events in ERBB2 signaling | |||
| 4 | PIP3 activates AKT signaling | |||
| 5 | GRB2 events in EGFR signaling | |||
| 6 | GAB1 signalosome | |||
| 7 | SHC1 events in EGFR signaling | |||
| 8 | EGFR downregulation | |||
| 9 | GRB2 events in ERBB2 signaling | |||
| 10 | PI3K events in ERBB2 signaling | |||
| 11 | EGFR Transactivation by Gastrin | |||
| 12 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
| 13 | Constitutive Signaling by EGFRvIII | |||
| 14 | RAF/MAP kinase cascade | |||
| 15 | Interleukin-6 signaling | |||
| 16 | Senescence-Associated Secretory Phenotype (SASP) | |||
| 17 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | |||
| 18 | Transcriptional regulation of pluripotent stem cells | |||
| 19 | Growth hormone receptor signaling | |||
| WikiPathways | ErbB Signaling Pathway | Click to Show/Hide | ||
| 2 | Regulation of Actin Cytoskeleton | |||
| 3 | EGF/EGFR Signaling Pathway | |||
| 4 | MAPK Signaling Pathway | |||
| 5 | Focal Adhesion | |||
| 6 | Aryl Hydrocarbon Receptor Pathway | |||
| 7 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 8 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
| 9 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| 10 | Bladder Cancer | |||
| 11 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 12 | Signaling by ERBB4 | |||
| 13 | Signaling by ERBB2 | |||
| 14 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| 15 | PIP3 activates AKT signaling | |||
| 16 | Nanoparticle-mediated activation of receptor signaling | |||
| 17 | Aryl Hydrocarbon Receptor | |||
| 18 | Spinal Cord Injury | |||
| 19 | Integrated Pancreatic Cancer Pathway | |||
| 20 | Gastric cancer network 2 | |||
| 21 | AGE/RAGE pathway | |||
| 22 | Signaling Pathways in Glioblastoma | |||
| 23 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
| 24 | miR-targeted genes in muscle cell - TarBase | |||
| 25 | miR-targeted genes in lymphocytes - TarBase | |||
| 26 | miR-targeted genes in epithelium - TarBase | |||
| 27 | Integrated Breast Cancer Pathway | |||
| 28 | Signaling by EGFR | |||
| 29 | L1CAM interactions | |||
| 30 | Serotonin Receptor 2 and STAT3 Signaling | |||
| 31 | Notch Signaling Pathway | |||
| 32 | Interferon type I signaling pathways | |||
| 33 | EPO Receptor Signaling | |||
| 34 | TGF Beta Signaling Pathway | |||
| 35 | IL-2 Signaling Pathway | |||
| 36 | IL-4 Signaling Pathway | |||
| 37 | IL-6 signaling pathway | |||
| 38 | Signaling of Hepatocyte Growth Factor Receptor | |||
| 39 | Kit receptor signaling pathway | |||
| 40 | Nuclear Receptors Meta-Pathway | |||
| 41 | Estrogen Receptor Pathway | |||
| 42 | IL-3 Signaling Pathway | |||
| 43 | Dopaminergic Neurogenesis | |||
| 44 | Transcriptional regulation of pluripotent stem cells | |||
| 45 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
| 46 | Signaling by SCF-KIT | |||
| 47 | Interleukin-6 signaling | |||
| 48 | Growth hormone receptor signaling | |||
| 49 | JAK/STAT | |||
| 50 | PDGF Pathway | |||
| 51 | BDNF signaling pathway | |||
| 52 | Oncostatin M Signaling Pathway | |||
| 53 | Adipogenesis | |||
| 54 | Interleukin-11 Signaling Pathway | |||
| 55 | Prostate Cancer | |||
| 56 | TSLP Signaling Pathway | |||
| 57 | IL-9 Signaling Pathway | |||
| 58 | IL17 signaling pathway | |||
| 59 | IL-7 Signaling Pathway | |||
| 60 | Regulation of Microtubule Cytoskeleton | |||
| 61 | Leptin signaling pathway | |||
| 62 | TSH signaling pathway | |||
| 63 | Cell Differentiation - Index | |||
| 64 | Cell Differentiation - meta | |||
| 65 | Signaling by PDGF | |||
| 66 | NGF signalling via TRKA from the plasma membrane | |||
| 67 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
| 68 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 69 | Physiological and Pathological Hypertrophy of the Heart | |||
| 70 | Androgen receptor signaling pathway | |||
| 71 | IL-5 Signaling Pathway | |||
